Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan vs Busulfan Conditioning in AML/MDS
NCT00822393Phase 3Completed
- Sponsor
- medac GmbH
- Start
- Nov 2008
- Primary completion
- Jan 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of treosulfan in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by medac GmbH. Primary endpoint: Event-Free Survival at 2 years. Started Nov 2008; status: completed.
02
Drugs
treosulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00822393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00822393.